"Stage specific trends in prostate cancer among men aged 40-54 years: A SEER analysis, 2004-2022".
文献摘要
Introduction Prostate cancer affects about 1 in 8 men, with incidence influenced by age and screening. Changes in prostate-specific antigen screening recommendations have coincided with changes in stage-specific prostate cancer incidence in the United States. However, contemporary stage-specific incidence trends among men aged 40-54 years remain incompletely characterized. We evaluated temporal trends in stage-specific prostate cancer incidence among men aged 40-54 years from 2004 to 2022. Methods A non-concurrent, population-based cohort study used the Surveillance, Epidemiology, and End Results (SEER) database (2004-2022). Of 86,894 men aged 40-54 years with microscopically confirmed prostate cancer, 84,554 men remained after excluding missing stage, autopsy-only reports, and death certificate-only reports. The primary exposure was year of diagnosis (continuous and eras: 2004-2011, 2012-2022, 2004-2022). The primary outcome was stage at diagnosis (localized, regional, distant). Analyses included delay-adjusted incidence rates, log-linear regression for annual percent change (APC) with 95% confidence intervals (CI), era-based comparisons, and chi-square testing. Cohort characteristics were described by age group, race/ethnicity, urbanicity, and marital status. Results Localized incidence significantly declined across all groups, while regional incidence significantly increased in the 45-49 (APC 3.63%; 95% CI 0.91-6.42) and 50-54 (APC 4.99%; 95% CI 3.90-6.08) age groups, and distant-stage incidence significantly increased in the 45-49 (APC 2.70%; 95% CI 2.15-3.26) and 50-54 (APC 2.93%; 95% CI 2.33-3.53) age groups. Neither regional or distant-stage incidence changed significantly among men aged 40-44 years. From 2004-2011, localized incidence significantly increased in the 45-49 group (APC 2.53%; 95% CI 0.01-5.12). From 2012-2022, localized incidence declined in the 40-44 (APC -5.58%; 95% CI -8.22 to -2.87) and 45-49 (APC -2.98%; 95% CI -5.14 to - 0.78) groups. Conclusion Localized prostate cancer incidence declined while regional and distant-stage incidence increased among men aged 40-54 years. Although multiple factors may contribute to these trends, the findings support further assessment of risk-adapted screening approaches in this population.